Mesenchymal stromal cells in tumor microenvironment remodeling of BCR-ABL negative myeloproliferative diseases.
JAK - STAT signaling pathway
mesenchymal stromal cells
myeloproliferative cancer
oxidative stress
tumor microenvironment
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2023
2023
Historique:
received:
10
01
2023
accepted:
13
02
2023
entrez:
13
3
2023
pubmed:
14
3
2023
medline:
14
3
2023
Statut:
epublish
Résumé
Chronic myeloproliferative neoplasms encompass the BCR-ABL1-negative neoplasms polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF). These are characterized by calreticulin (CALR), myeloproliferative leukemia virus proto-oncogene (MPL) and the tyrosine kinase Janus kinase 2 (JAK2) mutations, eventually establishing a hyperinflammatory tumor microenvironment (TME). Several reports have come to describe how constitutive activation of JAK-STAT and NFκB signaling pathways lead to uncontrolled myeloproliferation and pro-inflammatory cytokines secretion. In such a highly oxidative TME, the balance between Hematopoietic Stem Cells (HSCs) and Mesenchymal Stromal Cells (MSCs) has a crucial role in MPN development. For this reason, we sought to review the current literature concerning the interplay between HSCs and MSCs. The latter have been reported to play an outstanding role in establishing of the typical bone marrow (BM) fibrotic TME as a consequence of the upregulation of different fibrosis-associated genes including PDGF- β upon their exposure to the hyperoxidative TME characterizing MPNs. Therefore, MSCs might turn to be valuable candidates for niche-targeted targeting the synthesis of cytokines and oxidative stress in association with drugs eradicating the hematopoietic clone.
Identifiants
pubmed: 36910610
doi: 10.3389/fonc.2023.1141610
pmc: PMC9996158
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
1141610Informations de copyright
Copyright © 2023 La Spina, Giallongo, Giallongo, Vicario, Duminuco, Parenti, Giuffrida, Longhitano, Li Volti, Cambria, Di Raimondo, Musumeci, Romano, Palumbo and Tibullo.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Leuk Res. 2013 Feb;37(2):214-20
pubmed: 23174192
Prog Mol Subcell Biol. 2021;59:13-25
pubmed: 34050860
Rev Med Interne. 2013 Jun;34(6):369-72
pubmed: 23357690
Front Immunol. 2021 Dec 17;12:784401
pubmed: 34975874
Nucleic Acids Res. 2005 May 25;33(9):3057-64
pubmed: 15917437
Biol Blood Marrow Transplant. 2007 Jan;13(1 Suppl 1):64-72
pubmed: 17222772
Aging (Albany NY). 2021 Dec 14;13(23):25055-25071
pubmed: 34905501
Hemasphere. 2020 Jan 15;4(1):e333
pubmed: 32382708
Cell Stem Cell. 2015 Oct 1;17(4):422-34
pubmed: 26299573
J Biol Chem. 2000 Dec 29;275(52):41430-8
pubmed: 11007779
Nature. 2005 Apr 28;434(7037):1144-8
pubmed: 15793561
Leukemia. 2008 Jan;22(1):14-22
pubmed: 17882280
Int J Biochem Cell Biol. 2012 Jun;44(6):842-6
pubmed: 22373697
Blood. 2019 May 23;133(21):2320-2324
pubmed: 30745304
Nature. 2019 May;569(7755):222-228
pubmed: 30971824
Injury. 2016 Jun;47 Suppl 2:S11-20
pubmed: 27338221
Int J Mol Sci. 2022 Dec 02;23(23):
pubmed: 36499544
Blood. 2018 May 10;131(19):2111-2119
pubmed: 29572380
Haematologica. 2017 Jan;102(1):7-17
pubmed: 27909216
Biochimie. 2020 Apr - May;171-172:1-11
pubmed: 32004653
J Invest Dermatol. 2014 Jan;134(1):183-191
pubmed: 23771121
Nature. 2014 Aug 7;512(7512):78-81
pubmed: 25043017
J Cell Physiol. 2022 Jan;237(1):239-257
pubmed: 34435361
Ther Clin Risk Manag. 2012;8:95-103
pubmed: 22399854
Cancers (Basel). 2021 Jun 21;13(12):
pubmed: 34205678
Cell Death Dis. 2019 Sep 20;10(10):704
pubmed: 31541083
Blood. 2015 Aug 20;126(8):972-82
pubmed: 26022238
Cell Mol Life Sci. 2001 Oct;58(11):1627-35
pubmed: 11706989
Blood. 2005 Feb 1;105(3):973-7
pubmed: 15388582
Nature. 2014 Jan 16;505(7483):327-34
pubmed: 24429631
Cell Stem Cell. 2012 Mar 2;10(3):259-72
pubmed: 22385654
Cancer Cell. 2005 Apr;7(4):387-97
pubmed: 15837627
Hematol Oncol Stem Cell Ther. 2021 Sep;14(3):252-256
pubmed: 32201152
Curr Hematol Malig Rep. 2019 Jun;14(3):145-153
pubmed: 31119475
Mol Biol Rep. 2020 Dec;47(12):9951-9958
pubmed: 33141287
J Biol Chem. 2000 Apr 28;275(17):13089-97
pubmed: 10777614
Cell Stem Cell. 2017 Jun 1;20(6):785-800.e8
pubmed: 28457748
Blood. 2014 Jun 12;123(24):3714-9
pubmed: 24786775
Acta Histochem. 2014 Oct;116(8):1407-17
pubmed: 25307495
Clin Cancer Res. 2019 May 15;25(10):2956-2962
pubmed: 30655313
Eur J Pharmacol. 2001 Dec 21;433(2-3):225-30
pubmed: 11755156
Biology (Basel). 2021 Jul 13;10(7):
pubmed: 34356514
Leukemia. 2016 Feb;30(2):431-8
pubmed: 26449662
Am J Physiol Cell Physiol. 2006 Jan;290(1):C208-21
pubmed: 16135540
Blood. 2022 Dec 19;:
pubmed: 36534936
Cell. 2019 Jun 13;177(7):1915-1932.e16
pubmed: 31130381
Ann N Y Acad Sci. 2010 Aug;1203:120-5
pubmed: 20716293
Cell. 2007 Oct 19;131(2):324-36
pubmed: 17956733
J Clin Invest. 2022 Jun 1;132(11):
pubmed: 35439167
Proc Natl Acad Sci U S A. 2013 Jun 25;110(26):E2332-41
pubmed: 23754421
Nat Commun. 2020 Jul 20;11(1):3637
pubmed: 32686685
Leuk Lymphoma. 2019 Oct;60(10):2549-2557
pubmed: 30785365
J Tissue Viability. 2013 Nov;22(4):112-21
pubmed: 24050921
Cancers (Basel). 2020 Jan 30;12(2):
pubmed: 32019102
J Cell Physiol. 2018 May;233(5):3982-3999
pubmed: 28926091
Blood. 2019 Dec 19;134(25):2242-2248
pubmed: 31562135
Cancer. 2009 Sep 1;115(17):3842-7
pubmed: 19472396
Leuk Res. 2019 Jan;76:65-69
pubmed: 30578958
Hemasphere. 2021 Jun 01;5(6):e578
pubmed: 34095761
Proc Natl Acad Sci U S A. 2015 Aug 18;112(33):E4571-80
pubmed: 26243878
Antioxidants (Basel). 2020 Oct 23;9(11):
pubmed: 33114087
Leukemia. 2008 Jul;22(7):1308-19
pubmed: 18480833
Gels. 2020 Sep 30;6(4):
pubmed: 33008082
Proc Natl Acad Sci U S A. 2012 Jul 3;109(27):E1820-9
pubmed: 22689960
Mol Oncol. 2018 Dec;12(12):2102-2123
pubmed: 30259659
Hum Pathol. 2008 Jun;39(6):795-810
pubmed: 18538168
Cancer Res. 2015 Nov 15;75(22):4753-65
pubmed: 26404004
Redox Biol. 2020 Sep;36:101611
pubmed: 32863212
Biomedicines. 2022 Mar 30;10(4):
pubmed: 35453557
Biochem J. 1999 Dec 1;344 Pt 2:281-92
pubmed: 10567207
Cell Death Dis. 2020 Feb 7;11(2):109
pubmed: 32034134
Trends Immunol. 2009 Dec;30(12):592-602
pubmed: 19879803
Exp Biol Med (Maywood). 2011 Nov;236(11):1333-41
pubmed: 22036733
Nat Cell Biol. 2017 Jun;19(6):677-688
pubmed: 28481328
Mediterr J Hematol Infect Dis. 2018 Nov 01;10(1):e2018068
pubmed: 30416700
N Engl J Med. 2014 Jan 30;370(5):433-43
pubmed: 24350901
Haematologica. 2016 Jun;101(6):660-71
pubmed: 27252511
Cell Stem Cell. 2013 Sep 5;13(3):285-99
pubmed: 23850243
Cell Metab. 2020 Nov 3;32(5):829-843.e9
pubmed: 32966766
World J Stem Cells. 2014 Nov 26;6(5):526-39
pubmed: 25426250
Cell Stem Cell. 2021 Apr 1;28(4):637-652.e8
pubmed: 33301706
Adv Exp Med Biol. 2013;754:3-29
pubmed: 22956494
J Cell Mol Med. 2020 Oct;24(19):11100-11110
pubmed: 32889753
Biomolecules. 2021 Jan 19;11(1):
pubmed: 33477816
J Biol Chem. 2016 Nov 18;291(47):24607-24617
pubmed: 27758863
Mediators Inflamm. 2015;2015:415024
pubmed: 26640324
Front Immunol. 2021 Jun 01;12:683401
pubmed: 34140953
J Inflamm Res. 2020 Dec 02;13:1057-1073
pubmed: 33293849
N Engl J Med. 2005 Apr 28;352(17):1779-90
pubmed: 15858187
Br J Haematol. 2007 Mar;136(5):745-51
pubmed: 17313377